Inactive Instrument

Amarin Corporation plc (ADR) Stock Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

End-of-day quote Xetra
- EUR - Intraday chart for Amarin Corporation plc (ADR)
Sales 2024 * 233M 217M Sales 2025 * 252M 235M Capitalization 377M 351M
Net income 2024 * -50M -46.58M Net income 2025 * -29M -27.02M EV / Sales 2024 * 0.28 x
Net cash position 2024 * 313M 291M Net cash position 2025 * 315M 293M EV / Sales 2025 * 0.25 x
P/E ratio 2024 *
-7.34 x
P/E ratio 2025 *
-12.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.73%
More Fundamentals * Assessed data
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares. CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amarin Corporation plc authorizes a Buyback Plan. CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
More news

Latest transcript on Amarin Corporation plc (ADR)

Managers TitleAgeSince
Chief Executive Officer 52 23-07-17
Director of Finance/CFO 52 22-06-19
Compliance Officer 55 Nov. 14
Members of the board TitleAgeSince
Director/Board Member 45 23-02-27
Chairman 49 23-02-27
Director/Board Member 66 23-02-27
More insiders
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company